SCHEMBL26934005

SCHEMBL26934005

O=C(O)CCC1CN(Cc2ccccc2)CCC1=O

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 6/20 0.54
GRIN1 Q05586 1/20 0.46
GRIN2B Q13224 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
BCHE P06276 2/20 0.44
ACHE P22303 2/20 0.44
ALDH1A1 P00352 2/20 0.43
S1PR1 P21453 1/20 0.43
S1PR5 Q9H228 1/20 0.43
LTA4H P09960 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26933939 0.86 TACR1 (0.49) TACR1GRIN1GRIN2BSIGMAR1BCHE
SCHEMBL6042023 0.83 TACR1 (0.57) TACR1GRIN1GRIN2BSIGMAR1ACHE
SCHEMBL6042019 0.83 TACR1 (0.57) TACR1GRIN1GRIN2BSIGMAR1ACHE
SCHEMBL5870998 0.83 TACR1 (0.59) TACR1GRIN1GRIN2BSIGMAR1ALDH1A1
SCHEMBL12488908 0.82 TACR1 (0.56) TACR1GRIN1GRIN2BSIGMAR1S1PR1
SCHEMBL6041583 0.81 TACR1 (0.61) TACR1GRIN1GRIN2BSIGMAR1BCHE
SCHEMBL1618266 0.81 TACR1 (0.61) TACR1GRIN1GRIN2BSIGMAR1BCHE
SCHEMBL3545438 0.81 TACR1 (0.54) TACR1GRIN1GRIN2BSIGMAR1ALDH1A1
SCHEMBL1339508 0.80 TACR1 (0.59) TACR1GRIN1GRIN2BSIGMAR1ACHE
SCHEMBL28164936 0.80 TACR1 (0.59) TACR1GRIN1GRIN2BSIGMAR1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353863-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY INST NAT SANTE RECH MED (FR) 2025-11-20 US disclosed
EP-4536667-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY Institut National de la Santé et de la Recherche Médicale (FR) 2025-04-16 EP disclosed
WO-2023237580-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2023-12-14 WO disclosed
WO-2023237580-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353863-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY TALDO1, TBCA, TBCD TACR1 1620/4885GRIN1 4774/4885GRIN2B 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.